Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
硕迪生物2022年第四季度和全年财务业绩以及近期亮点
04 avr. 2023 19h00 HE
|
Structure Therapeutics Inc.
口服GLP-1激动剂GSBR-1290 Phase 1b研究已完成给药预计2023年下半年将获得GSBR-1290 Phase 1b和Phase 2a研究的数据已完成总额为1.853亿美元的扩大规模首次公开募股 旧金山和上海, April 05, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30 mars 2023 16h30 HE
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
02 févr. 2023 20h59 HE
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司(纳斯达克股票代码:GPCR)是一家临床阶段的全球化生物制药公司,致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日,公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票(ADS),每股ADS代表三股普通股,公开发行价格为每股ADS...
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
02 févr. 2023 19h41 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...